Trivalent influenza virus vaccine (TIV)

BIOLOGICAL2 trials

Sponsors

Novartis, Novartis Vaccines

Conditions

Human InfluenzaPandemic Influenza Disease

Phase 2

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

CompletedNCT01636102

Novartis VaccinesHuman Influenza

Start: 2012-07-31End: 2012-07-31Updated: 2015-11-30

Phase 3

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

CompletedNCT00841763

NovartisPandemic Influenza Disease

Start: 2008-10-31End: 2009-11-30Updated: 2021-04-23